The Conversation (0)
Genmab (Nasdaq:GEN) announced that worldwide net sales of DARZALEX (daratumumab) as reported by Johnson & Johnson were USD 1,242 million in 2017. As quoted in the press release: Net sales were USD 884 million in the U.S. and net sales in the rest of the world were USD 358 million. Genmab receives royalties on the …
Genmab (Nasdaq:GEN) announced that worldwide net sales of DARZALEX (daratumumab) as reported by Johnson & Johnson were USD 1,242 million in 2017.
As quoted in the press release:
Net sales were USD 884 million in the U.S. and net sales in the rest of the world were USD 358 million. Genmab receives royalties on the worldwide net sales of DARZALEX under the exclusive worldwide license to Janssen Biotech, Inc. to develop, manufacture and commercialize DARZALEX.
DARZALEX was approved in the U.S. in November 2015, in Europe in May 2016 and in Japan in September 2017. Worldwide net sales of DARZALEX in 2016 were USD 572 million, resulting in royalty income of DKK 458 million to Genmab.